Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.55 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.55 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 7/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.53 |
| ▸ | F2 | P00734 | 1/20 | 0.53 |
| ▸ | F12 | P00748 | 1/20 | 0.53 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.52 |
| ▸ | GRK6 | P43250 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CASP1 | P29466 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9107642 | 0.85 | CYP1A2 (0.59) | NR1H2NR1H3ADORA3CYP1A2MEN1 | |
| SCHEMBL15312405 | 0.85 | F2 (0.52) | CYP1A2MEN1ALDH1A1KMT2AF2 | |
| SCHEMBL17866359 | 0.85 | CA12 (0.47) | ADORA3CYP1A2MEN1ALDH1A1KMT2A | |
| SCHEMBL2561959 | 0.81 | MEN1 (0.55) | NR1H2NR1H3ADORA3CYP1A2MEN1 | |
| SCHEMBL10778891 | 0.81 | ADORA3 (0.54) | NR1H2NR1H3ADORA3CYP1A2MEN1 | |
| SCHEMBL2558305 | 0.81 | ADORA3 (0.55) | ADORA3CYP1A2ALDH1A1KMT2AADORA2A | |
| SCHEMBL17866362 | 0.79 | ADORA2A (0.59) | NR1H2NR1H3CYP1A2KDM4EADORA2A | |
| SCHEMBL21834365 | 0.78 | GRK6 (0.62) | NR1H2NR1H3ALDH1A1KDM4EADORA2A | |
| SCHEMBL5035408 | 0.78 | F2 (0.59) | MEN1ALDH1A1KMT2AKDM4EF2 | |
| SCHEMBL7059235 | 0.77 | ALDH1A1 (0.51) | ADORA3ALDH1A1KMT2AKDM4EADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834452-B2 | CXCR7 antagonists | CHEMOCENTRYX, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| US-11834452-B2 | CXCR7 antagonists | CHEMOCENTRYX, INC. (US) | 2023-12-05 | — | — | US | disclosed |
| WO-2022137033-A1 | ORGANIC METAL COMPLEX, LIGHT-EMITTING DEVICE, LIGHT-EMITTING APPARATUS, ELECTRONIC EQUIPMENT, AND ILLUMINATION APPARATUS | 株式会社半導体エネルギー研究所 | 2022-06-30 | — | — | WO | disclosed |
| WO-2022090863-A1 | ORGANIC COMPOUND, CARRIER TRANSPORT MATERIAL, HOST MATERIAL, LIGHT EMITTING DEVICE, LIGHT EMITTING APPARATUS, ELECTRONIC EQUIPMENT, AND LIGHTING APPARATUS | 株式会社半導体エネルギー研究所 | 2022-05-05 | — | — | WO | disclosed |
| US-20220127272-A1 | CXCR7 ANTAGONISTS | CHEMOCENTRYX, INC. | 2022-04-28 | — | — | US | disclosed |
| WO-2022053905-A1 | ORGANIC METAL COMPLEX, LIGHT-EMITTING DEVICE, LIGHT-EMITTING APPARATUS, ELECTRONIC EQUIPMENT, AND LIGHTING DEVICE | 株式会社半導体エネルギー研究所 | 2022-03-17 | — | — | WO | disclosed |
| US-11059825-B2 | CXCR7 antagonists | CHEMOCENTRYX, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-10287292-B2 | CXCR7 antagonists | CHEMOCENTRYX, INC. (US) | 2019-05-14 | — | — | US | disclosed |
| EP-2925745-B1 | CXCR7 ANTAGONISTS | CHEMOCENTRYX INC (US) | 2018-04-04 | — | — | EP | disclosed |
| US-20180086766-A1 | CXCR7 ANTAGONISTS | CHEMOCENTRYX, INC. | 2018-03-29 | — | — | US | disclosed |
| EP-1628971-B1 | TRIAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-05-07 | — | — | EP | disclosed |
| US-7223780-B2 | Triazole-derivatives as blood clotting enzyme factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-05-29 | — | — | US | disclosed |
| EP-1628971-A1 | TRIAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-03-01 | — | — | EP | disclosed |
| US-20050009827-A1 | Carboxamide derivatives of 1,2,3- and 1,2,4-triazoles and 1H- and 2H-tetrazoles, e.g., 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-pyrrol-1-yl-1H-[1,2,4]triazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-01-13 | — | — | US | disclosed |
| WO-2004101555-A1 | TRIAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-11-25 | — | — | WO | disclosed |
| EP-1479679-A1 | Triazole-derivatives as factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-11-24 | — | — | EP | disclosed |
| EP-0645023-A1 | IMAGEABLE ARTICLES HAVING DYE SELECTIVE INTERLAYERS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-03-29 | — | — | EP | disclosed |
| WO-1993025936-A2 | IMAGEABLE ARTICLES HAVING DYE SELECTIVE INTERLAYERS | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1993-12-23 | — | — | WO | disclosed |
| CN-1058694-A | Contain 1,2, the Herbicidal combinations of 4-triazole-3-formamide and control method for weed with said composition | KUREHA CHEMICAL IND CO LTD (JP) | 1992-02-19 | — | — | CN | disclosed |
| CN-86108483-A | 1. 2, 4-triazole-3-carboxamide compound, preparation method thereof and herbicidal composition containing same | — | 1987-09-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10287292-B2 | CXCR7 antagonists | CXCR1, CXCR5, CCR7 | NR1H2 77/4885NR1H3 72/4885ADORA3 257/4885 |
| US-20050009827-A1 | Carboxamide derivatives of 1,2,3- and 1,2,4-triazoles and 1H- and 2H-tetrazoles, e.g., 1-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-5-pyrrol-1-yl-1H-[1,2,4]triazole-3-carboxylic acid (1-isopropyl-piperidin-4-yl)-amide | TFPI, F11, TFPI2 | NR1H2 2559/4885NR1H3 2564/4885ADORA3 466/4885 |
| US-20180086766-A1 | CXCR7 ANTAGONISTS | CXCR1, CXCR5, CCR7 | NR1H2 77/4885NR1H3 72/4885ADORA3 257/4885 |
| US-11059825-B2 | CXCR7 antagonists | CXCR1, CXCR5, CCR7 | NR1H2 77/4885NR1H3 72/4885ADORA3 257/4885 |
| US-11834452-B2 | CXCR7 antagonists | CXCR1, CXCR5, CCR7 | NR1H2 77/4885NR1H3 72/4885ADORA3 257/4885 |
| US-20220127272-A1 | CXCR7 ANTAGONISTS | CXCR1, CXCR5, CCR7 | NR1H2 77/4885NR1H3 72/4885ADORA3 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.